Last reviewed · How we verify

IV Neostigmine Methylsulfate + Atropine Sulphate

Damanhour Teaching Hospital · FDA-approved active Small molecule

IV Neostigmine Methylsulfate + Atropine Sulphate is a Acetylcholinesterase inhibitor + Antimuscarinic Small molecule drug developed by Damanhour Teaching Hospital. It is currently FDA-approved for Myasthenia gravis, Reversal of neuromuscular blockade, Postoperative ileus. Also known as: Neostigmine ampoule, Atropine ampoule.

Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while atropine blocks muscarinic receptors to prevent cholinergic toxicity.

Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while atropine blocks muscarinic receptors to prevent cholinergic toxicity. Used for Myasthenia gravis, Reversal of neuromuscular blockade, Postoperative ileus.

At a glance

Generic nameIV Neostigmine Methylsulfate + Atropine Sulphate
Also known asNeostigmine ampoule, Atropine ampoule
SponsorDamanhour Teaching Hospital
Drug classAcetylcholinesterase inhibitor + Antimuscarinic
TargetAcetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (atropine)
ModalitySmall molecule
Therapeutic areaNeurology
PhaseFDA-approved

Mechanism of action

Neostigmine methylsulfate is a reversible acetylcholinesterase inhibitor that increases acetylcholine concentration at the neuromuscular junction and autonomic sites. Atropine sulphate is a muscarinic antagonist co-administered to block the unwanted parasympathomimetic effects (salivation, bronchospasm, bradycardia) of excess acetylcholine while preserving the beneficial nicotinic effects at the neuromuscular junction.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about IV Neostigmine Methylsulfate + Atropine Sulphate

What is IV Neostigmine Methylsulfate + Atropine Sulphate?

IV Neostigmine Methylsulfate + Atropine Sulphate is a Acetylcholinesterase inhibitor + Antimuscarinic drug developed by Damanhour Teaching Hospital, indicated for Myasthenia gravis, Reversal of neuromuscular blockade, Postoperative ileus.

How does IV Neostigmine Methylsulfate + Atropine Sulphate work?

Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while atropine blocks muscarinic receptors to prevent cholinergic toxicity.

What is IV Neostigmine Methylsulfate + Atropine Sulphate used for?

IV Neostigmine Methylsulfate + Atropine Sulphate is indicated for Myasthenia gravis, Reversal of neuromuscular blockade, Postoperative ileus, Urinary retention.

Who makes IV Neostigmine Methylsulfate + Atropine Sulphate?

IV Neostigmine Methylsulfate + Atropine Sulphate is developed and marketed by Damanhour Teaching Hospital (see full Damanhour Teaching Hospital pipeline at /company/damanhour-teaching-hospital).

Is IV Neostigmine Methylsulfate + Atropine Sulphate also known as anything else?

IV Neostigmine Methylsulfate + Atropine Sulphate is also known as Neostigmine ampoule, Atropine ampoule.

What drug class is IV Neostigmine Methylsulfate + Atropine Sulphate in?

IV Neostigmine Methylsulfate + Atropine Sulphate belongs to the Acetylcholinesterase inhibitor + Antimuscarinic class. See all Acetylcholinesterase inhibitor + Antimuscarinic drugs at /class/acetylcholinesterase-inhibitor-antimuscarinic.

What development phase is IV Neostigmine Methylsulfate + Atropine Sulphate in?

IV Neostigmine Methylsulfate + Atropine Sulphate is FDA-approved (marketed).

What are the side effects of IV Neostigmine Methylsulfate + Atropine Sulphate?

Common side effects of IV Neostigmine Methylsulfate + Atropine Sulphate include Muscle fasciculations, Increased salivation (despite atropine), Bronchospasm, Bradycardia, Nausea and vomiting, Abdominal cramping.

What does IV Neostigmine Methylsulfate + Atropine Sulphate target?

IV Neostigmine Methylsulfate + Atropine Sulphate targets Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (atropine) and is a Acetylcholinesterase inhibitor + Antimuscarinic.

Related